Rapid Therapeutic Science Laboratories (RTSL) Stock Statistics & Valuation Metrics
Total Valuation
Rapid Therapeutic Science Laboratories has a market cap or net worth of $3,533.00. The enterprise value is $3.45T.
- Market Cap
- $3,533.00
- Enterprise Value
- $3.45T
Share Statistics
Rapid Therapeutic Science Laboratories has 8,832,251 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 8,832,251
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Rapid Therapeutic Science Laboratories’s return on equity (ROE) is 0.54 and return on invested capital (ROIC) is -173.00%.
- Return on Equity (ROE)
- 0.54
- Return on Assets (ROA)
- -0.75
- Return on Invested Capital (ROIC)
- -173.00%
- Return on Capital Employed (ROCE)
- 0.47
- Revenue Per Employee
- 0
- Profits Per Employee
- -564.60K
- Employee Count
- 3
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Rapid Therapeutic Science Laboratories is -0.04. Rapid Therapeutic Science Laboratories’s PEG ratio is -0.00.
- PE Ratio
- -0.04
- PS Ratio
- 0.00
- PB Ratio
- -0.00
- Price to FCF
- -0.00
- Price to Operating Cash Flow
- -0.01
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Rapid Therapeutic Science Laboratories had revenue of 0 and earned -1.69M in profits. Earnings per share was -0.22.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -1.26M
- Pretax Income
- -1.79M
- Net Income
- -1.69M
- EBITDA
- -1.24M
- Earnings Per Share (EPS)
- -0.22
Cash Flow
In the last 12 months, operating cash flow was -566.60K and capital expenditures -249,581, giving a free cash flow of -816.19K billion.
- Operating Cash Flow
- -566.60K
- Free Cash Flow
- -816.19K
- Free Cash Flow per Share
- -0.06
Dividends & Yields
Rapid Therapeutic Science Laboratories pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -33706.88%
- Earnings Yield
- -2374.67%
Stock Price Statistics
- Beta
- -5.24
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- 325.47K
Financial Position
Rapid Therapeutic Science Laboratories as a current ratio of 0.05, with Debt / Equity ratio of -121.94%
- Current Ratio
- 0.05
- Quick Ratio
- 0.01
- Debt to Market Cap
- 0.59
- Net Debt to EBITDA
- -3.09
- Interest Coverage Ratio
- -0.67
Taxes
In the past 12 months, Rapid Therapeutic Science Laboratories has paid -100.92K in taxes.
- Income Tax
- -100.92K
- Effective Tax Rate
- 0.06
Enterprise Valuation
Rapid Therapeutic Science Laboratories EV to EBITDA ratio is -58.24, with an EV/FCF ratio of -2.90.
- EV to Sales
- 0.00
- EV to EBITDA
- -58.24
- EV to Free Cash Flow
- -2.90
- EV to Operating Cash Flow
- -3.00
Balance Sheet
Rapid Therapeutic Science Laboratories has $2,160.00 in cash and marketable securities with $3.79M in debt, giving a net cash position of -$3.78M billion.
- Cash & Marketable Securities
- $2,160.00
- Total Debt
- $3.79M
- Net Cash
- -$3.78M
- Net Cash Per Share
- -$0.43
- Tangible Book Value Per Share
- -$0.35
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Rapid Therapeutic Science Laboratories is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―